Metabolic and toxicological considerations of newly approved prostate cancer drugs
Author:
Publisher
Informa Healthcare
Subject
Pharmacology,Toxicology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1517/17425255.2013.789019
Reference41 articles.
1. STUDIES ON PROSTATIC CANCER
2. Overcoming castration resistance in prostate cancer
3. The 16,17-Double Bond Is Needed for Irreversible Inhibition of Human Cytochrome P45017α by Abiraterone (17-(3-Pyridyl)androsta-5,16-dien-3β-ol) and Related Steroidal Inhibitors
4. Abiraterone Inhibits 3β-Hydroxysteroid Dehydrogenase: A Rationale for Increasing Drug Exposure in Castration-Resistant Prostate Cancer
5. Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer;Cancers;2020-07-01
2. Enzalutamide and cancer;Eurasian Journal of Medicine and Oncology;2018
3. A case report of enzalutamide administration in a dialysis-dependent patient with castration-resistant prostate cancer;Journal of Oncology Pharmacy Practice;2017-02-01
4. Enzalutamide (Xtandi): An Androgen Receptor Antagonist for Late-Stage Prostate Cancer;Innovative Drug Synthesis;2015-12-11
5. Is prostate cancer changing?: Evolving patterns of metastatic castration-resistant prostate cancer;Cancer;2013-12-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3